Stockwinners Market Radar for October 24, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:10 EDT Cathie Wood's ARK Investment buys 308.1K shares of Cerus today

20:07 EDT Cathie Wood's ARK Investment sells 85.4K shares of Tesla today

19:50 EDT Kaixin Auto trading halted, news pending

18:29 EDT Fiserv director sells $8.1M in common stock - In a regulatory filing, Fiserv disclosed that its director Doyle Simons sold 40K shares of common stock on October 23rd in a total transaction size of $8.1M.

18:23 EDT Meta CLO Newstead sells 905 class A shares - In a regulatory filing, Meta chief legal officer Jennifer Newstead disclosed the sale of 905 class A common shares of the company on October 22 at a price of $574.70 per share.

18:02 EDT Community Healthcare raises quarterly dividend to 46.5c per share - Community Healthcare Trust announced that its Board of Directors has increased its common stock cash dividend for the quarter ended September 30. This dividend, in the amount of 46.5c per share, is payable on November 22 to shareholders of record on November 8. This dividend rate equates to an annualized dividend of $1.86 per share. Community Healthcare Trust has increased its dividend every quarter since its Initial Public Offering.

17:52 EDT Tapestry issues statement on district court ruling, intends to appeal - Tapestry (TPR) issued the following statement in response to the ruling made by the U.S. District Court in the Southern District of New York regarding Tapestry's proposed acquisition of Capri Holdings (CPRI): "Today's decision granting the FTC's request for a preliminary injunction is disappointing and, we believe, incorrect on the law and the facts. Tapestry and Capri operate in an industry that is intensely competitive and dynamic, constantly expanding, and highly fragmented among both established players and new entrants. We face competitive pressures from both lower- and higher-priced products and continue to believe this transaction is pro-competitive and pro-consumer. We intend to appeal the decision, consistent with our obligations under the merger agreement."

17:36 EDT Spirit Airlines sees Q3 capacity down 1.2% y/y - In a regulatory filing, the company states: "On October 18, 2024, Spirit Airlines entered into a binding term sheet with GA Telesis, LLC for the sale of 23 A320ceo/A321ceo aircraft to GAT for an expected total purchase price of approximately $519 million. The Aircraft are planned for delivery beginning in October 2024 through February 2025. On October 24, 2024, Spirit Airlines, Inc. provided an update to investors announcing certain preliminary estimates for the third quarter 2024. The Company's unaudited interim consolidated financial statements for the third quarter 2024 are not yet complete and results may vary from these preliminary estimates upon completion of closing procedures. The Company estimates the net proceeds of the Sale, combined with discharging the Aircraft-related debt from its balance sheet, will benefit its liquidity by approximately $225 million through year-end 2025. The Company estimates its third quarter 2024 adjusted operating margin will come in approximately three hundred basis points better than the mid-point of its previous guidance range, primarily due to stronger-than-expected revenue with early results from its transformation plan exceeding initial expectations. The Company's third quarter 2024 capacity was down 1.2 percent year over year, and the Company estimates its fourth quarter 2024 capacity will be down approximately 20 percent year over year. The Company plans to provide additional details regarding its third quarter 2024 performance in conjunction with reporting its third quarter results which it plans to release in mid-November. For the full year 2025, the Company estimates its capacity will be down mid-teens year over year. This decrease takes into account the sale and removal from scheduled service of the Aircraft, a year-over-year increase in the estimated number of neo aircraft removed from scheduled service due to the reduced availability of Pratt & Whitney geared turbofan engines, the retirement of the Company's remaining A319ceo aircraft and the addition of six new A321neo aircraft scheduled for delivery in 2025. As part of its continued strategy to return to profitability, the Company has identified approximately $80 million of annualized cost reductions that it plans to begin implementing in early 2025. These cost reductions are driven primarily by a reduction in workforce commensurate with the Company's expected flight volume. As previously disclosed, the Company remains in active and constructive discussions with holders of its senior secured notes due 2025 and convertible senior notes due 2026 with respect to their respective maturities."

17:18 EDT Primis Financial receives notice of delisting stay extension from Nasdaq - Primis Financial received a notice from Nasdaq indicating that the temporary stay of delisting of the company's common stock has been extended pending a hearing before the Nasdaq Hearings Panel on December 3, 2024, and the issuance of a final Panel decision. On October 3, the company received a notice from Nasdaq indicating that the company's common stock would be delisted because the company did not timely file several required documents. On October 8, the company appealed Nasdaq's determination in the Delisting Notice and requested a hearing. The Hearing Request had temporarily stayed any suspension or delisting action until October 24, and requested that the temporary stay be extended until the Panel issues a final decision on the matter. The company filed the Form 10-K on October 15 and is working diligently to file the Form 10-Qs as promptly as practicable.

17:02 EDT Lilium board approves application for self-administration of German units - Lilium N.V. announced that its principal German subsidiaries will apply for self-administration proceedings in the next few days with the competent court in Germany. This follows a lengthy and complex government approval process for a loan from KfW, which failed in the Budget Committee of the German parliament. Lilium's international competition is receiving grants and loans in the U.S., France, China, Brazil, and the UK. Therefore, German government support was seen by Lilium investors as critical to retain market confidence and potential future investment. "Our plan was to obtain shareholder investment in a new funding round anchored by a German government backed loan of EUR 100 million," Lilium CEO Klaus Roewe said. "We had already conditionally secured additional private capital to complement the KfW loan. However, the Budget Committee was unable to agree on the loan and Bavaria couldn't do it alone." German government support of the KfW loan was a closing condition to already committed private funding and without this support Lilium was left with no alternative but to cause the principal German subsidiaries to file for self-administration. Lilium was also in advanced discussions regarding a French government guarantee of a EUR 219M loan to finance a battery factory and an assembly line in the Southwest of France. Following the Lilium Jet's planned first flight in early 2025, Lilium anticipated receiving pre-delivery payments and new investment to finance the company into 2026 when the company expected delivery would begin on its current order pipeline consisting of firm orders, reservations, options, and memoranda of understanding for more than 780 Lilium Jets to operators in the U.S., South America, Europe, Asia, and the Middle East.

16:57 EDT Epsilon Energy enters province of Alberta through two joint ventures - Epsilon Energy reported the signing of definitive agreements to form a joint venture in the Garrington and Harmattan areas of Alberta, Canada, in the Western Canadian Sedimentary Basin. In partnership with a Calgary-based private operator, Epsilon will earn a 25% working interest in undeveloped lands, covering approximately 30,000 gross acres in the Garrington area, targeting horizontal development of the liquids-focused Glauconitic and Ellerslie formations, and approximately 130,000 gross acres in the Harmattan area, targeting horizontal development of the liquids-focused Upper Viking formation. The company estimates the joint venture area holds over 25 2-mile locations in the Mannville. Offset wells exhibit attractive economics, driven by mid-teens effective royalty rates and drilling and completion costs per well estimated at $600-700 CAD per completed lateral foot. The large contiguous Harmattan acreage is more speculative due to varied historical results but represents a large upside opportunity through multiple targets and potential completion optimization. Consideration will be in the form of up to a C$12M development carry, with C$10M to be deployed over a minimum of four gross horizontal wells, drilled and completed over a 12-month period from December 1 with the operator's option for two additional gross horizontal wells, drilled and completed over a 12-month period from December 1, 2025. The operator will maintain a minimum 20% working interest during the carry period. Additionally, the company entered a joint venture in the Killam area of Alberta, Canada, in the Western Canadian Sedimentary Basin in April. In partnership with a different Calgary-based private operator, Epsilon acquired a 50% working interest in undeveloped lands, covering 14,000 gross acres, targeting development of the liquids-focused Mannville formation. Consideration was C$1.4M and the company committed to participate in two wells during 2024. The project is a proof of application of multi-leg open hole horizontal wells which have proven successful in other parts of Alberta. The drilling of the initial two wells in August and September has yielded one commercial discovery currently on production and a second prospect unable to be properly evaluated due to mechanical issues. Gross drilling and completion costs are approximately C$2M per well.

16:49 EDT AppFolio names Tim Eaton as interim CFO - The company states: "On October 23, 2024, Fay Sien Goon, the Chief Financial Officer of the Company, notified the Company's Board of Directors of her plans to depart the Company as of October 25, 2024. Ms. Goon's departure is not related to any financial or accounting issue or the result of any disagreement with respect to the Company's operations, policies, or practices. The Company has commenced a search for a successor to Ms. Goon and will consider internal and external candidates. Pending the appointment of Ms. Goon's successor, the Board, on October 23, 2024, appointed Tim Eaton as the Company' interim Chief Financial Officer effective as of the Separation Date. Mr. Eaton, 36, has served as the Company's Chief of Staff to the Chief Executive Officer since 2022, and in various other leadership roles within the Company since 2020. "

16:41 EDT L3Harris Technologies up 4% at $254.30 after Q3 results, adjusted FY24 guidance

16:39 EDT L3Harris Technologies reports Q3 orders $7.2B - Reports Q3 book-to-bill of 1.4-times.

16:36 EDT Medtronic's Affera ablation system granted FDA approval - Medtronic announced FDA approval of the Affera Mapping and Ablation System with Sphere-9 Catheter, an all-in-one, high-density mapping and pulsed field and radiofrequency ablation catheter for treatment of persistent atrial fibrillation and for RF ablation of cavotricuspid isthmus dependent atrial flutter. With this approval, Medtronic is now the first and only company with two PFA technologies available for patients with Afib. AFib is one of the most common and undertreated heart rhythm disorders, affecting more than 60 million people worldwide.

16:34 EDT Middlesex Water increases quarterly dividend 4.62% to 34c per share - Middlesex Water announced that its board has declared a quarterly cash dividend of 34c per share on its common stock, a 4.62% increase from the 32.5c per share dividend last declared in July. This increase raises the annual dividend rate to $1.36 from $1.30 per share of common stock and marks Middlesex's 52nd consecutive year of dividend increases. The dividend at the new rate is payable December 2 to shareholders of record as of November 15. Middlesex Water Company has paid cash dividends in varying amounts continually since 1912.

16:31 EDT Murphy USA raises quarterly dividend by 6.7% to 48c per share - The dividend is payable on December 2, 2024, to stockholders of record as of November 4, 2024.

16:28 EDT Coursera announces plans to reduce global workforce by 10% - Coursera announced a "commitment to reducing overall expenses, focusing efforts, and prioritizing future investments in key initiatives that are expected to drive long-term, sustainable growth." It expects this initiative to generate at least $30M in annualized structural cost savings as well as incremental profitability that will be reflected in its full year 2025 financial outlook to be provided on its Q4 earnings release. In connection with this effort, Coursera plans to reduce its global workforce by approximately 10% "to better align our cost structure and personnel needs with our business objectives, growth opportunities, and operational priorities."

16:24 EDT Exponent declares regular quarterly dividend of 28c per share - Exponent announced that its Board of Directors has declared a quarterly cash dividend of 28c per share of common stock to be paid on December 20 to all common stockholders of record as of December 6 . Exponent has paid, and expects to continue to pay, quarterly dividends each year in March, June, September, and December. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to the final determination of Exponent's Board of Directors. "Exponent is proud to execute on our commitment to shareholders through our regular quarterly cash dividend," commented Dr. Catherine Corrigan, President and Chief Executive Officer. "Strengthened by the power of our diverse services portfolio, along with our successful alignment of our operating model, Exponent is uniquely positioned to capture market demand and deliver long-term value to our shareholders."

16:21 EDT Hartford Financial raises quarterly dividend 11% to 52c per share - Hartford Financial has increased the quarterly common dividend per share by 11%, to 52c, payable Jan. 3, 2025 to shareholders of record at the close of business on Dec. 2, 2024.

16:15 EDT Kinsale Capital board authorizes repurchase of up to $100M of common stock - In October 2024, the Company's Board of Directors authorized a share repurchase program authorizing the repurchase of up to $100.0 million of the Company's common stock. The shares may be repurchased from time to time in open market purchases, privately-negotiated transactions, block purchases, accelerated share repurchase agreements or a combination of methods and pursuant to safe harbors provided by Rule 10b-18 and Rule 10b5-1 under the Securities Exchange Act of 1934. The timing, manner, price and amount of any repurchases under the share repurchase program will be determined by the Company in its discretion. The stock repurchase program does not require the Company to repurchase any specific number of shares, and may be modified, suspended or terminated at any time.

16:13 EDT Aeries Technology regains compliance with Nasdaq - Aeries Technology announced that it has received written notice from the staff of the Listing Qualifications Department of Nasdaq informing the company that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) regarding periodic reporting.

16:10 EDT Comfort Systems USA raises quarterly dividend to 35c per share from 30c - The dividend is payable on November 25, 2024 to stockholders of record at the close of business on November 14, 2024.

16:09 EDT Texas Roadhouse backs FY24 comparable restaurant sales view of positive growth - Backs FY24 capital expenditures view $360M-$370M.

16:07 EDT Capri Holdings down 52% in after-hours trading - Shares of Capri Holdings have plunged $21.62, or 52%, to $19.98 in after-hours trading.

16:02 EDT Leidos receives success memorandum from Defense Innovation Unit - Leidos announced it has received a success memorandum from the Defense Innovation Unit for the completion of key milestones in its Electric Vehicle Charging as a Service prototype for the Department of the Air Force. This milestone establishes Leidos as the sole vendor authorized by the DIU to provide a FedRAMP-accredited budget-neutral EV CaaS solution for the Department of Defense and the U.S. government.

15:06 EDT INmune Bio announces publication of XPro1595 data in Cell Reports - INmune Bio announced the publication of a seminal paper in the journal Cell Reports that demonstrates XPro1595 promotes remyelination in an animal model of demyelinating disease. The study was performed under the direction of Leslie Probert, head of immunology at the Hellenic Pasteur Institute in Athens Greece, and is the culmination of several years of work supported by EU research grants. Myelin is necessary for fast and efficient communication between neurons. Loss of myelin compromises neuron function and communication and is a step in the neurodegenerative process of many CNS diseases, including Alzheimer's Disease.

15:03 EDT Advent Technologies board approves termination of Vassilios Gregoriou as CEO - According to a regulatory filing, on October 24, 2024, the Board of Directors of Advent Technologies Holdings approved the termination of the employment of Vassilios Gregoriou, the Chief Executive Officer, Acting Chief Financial Officer, for cause, effective immediately. Further to the said termination, in connection with Gregoriou's termination, the company's board of directors appointed Gary Herman, who is currently serving as the company's Class I Director, to the additional role of interim chief executive officer, effective immediately, until a new Chief Executive Officer is appointed. Information regarding Herman's age, background, and experience is incorporated by reference to the company's Current Report on Form 8-K filed on September 4, 2024.

14:55 EDT Summit Materials jumps after Bloomberg says Quikrete made takeover approach - Shares of Summit are up $5.07, or 12.5%, to $45.69 following Bloomberg's report.

14:18 EDT DOJ, DOT launch broad public inquiry into state of competition in air travel - The Justice Department's Antitrust Division and Department of Transportation jointly announced a broad public inquiry into the state of competition in air travel. The agencies are seeking public information on consolidation, anticompetitive conduct and a wide range of issues affecting the availability and affordability of air travel options. The topics covered in the agencies' joint Request for Information include previous airline mergers, exclusionary conduct, airport access, aircraft manufacturing, airline ticket sales, pricing and rewards practices and the experiences of aviation workers. The agencies jointly issued the RFI requesting public comments explaining how the air travel industry has been impacted by consolidation and anticompetitive practices and identifying ways to address any harms to competition. The public will have 60 days to submit comments at Regulations.gov, no later than Dec. 23. Once submitted, comments will be posted to Regulations.gov. All market participants are invited to provide comments in response to this RFI, including passengers, consumer advocates, pilots, in-flight and ground crews, airport authorities, employers, airlines, private and charter aircraft operators, travel agents, trade groups, industry analysts, purchasers of corporate travel services and other entities that provide or rely upon air travel services. Publicly traded companies in the space include Alaska Air (ALK), American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU), Southwest (LUV), Spirit Airlines (SAVE) and United Airlines (UAL).Reference Link

13:58 EDT GSK to invest up to $800M in Pennsylvania site - GSK plc announced what it calls its "largest U.S. manufacturing investment to date." The up to $800M investment will bring state-of-the-art drug substance manufacturing and additional drug product manufacturing capabilities to the company's site in Marietta, Pennsylvania, along with over 200 new jobs, the company stated. "The new multi-purpose facility will be capable of manufacturing sterile liquid vaccines and medicines for which there is ever-increasing demand. This facility will also house a state-of-the-art R&D pilot plant to manufacture medicines for clinical trials. Additionally, GSK will establish a new vaccines drug substance facility at the site, dedicated to manufacturing products based on the company's novel MAPS technology, subsequent to future regulatory submissions and approvals. This expansion will double the size and capacity of the Marietta site," said GSK. Regis Simard, President Global Supply Chain, GSK, said: "This landmark investment will establish Marietta as an innovation and manufacturing hub capable of delivering next generation medicines and vaccines to people around the world. We're grateful for the support of local and state officials, who made this project possible, and we are excited to expand upon the important work already underway at the Marietta site."

13:13 EDT Inspector General finds overpayments to Medicare Advantage companies - The Department of Health and Human Services' Office of Inspector General found that taxpayers fund billions of dollars in overpayments to Medicare Advantage companies each year based on unsupported diagnoses for enrollees. Twenty Medicare Advantage companies each had a share of payments from health risk assessments and HRA-linked chart reviews that exceeded their percentage of enrollees by more than 25%, the agency said in a report. Taken together, these 20 companies generated 80%, or $6B of $7.5B, of the estimated 2023 risk-adjusted payments from HRAs and HRA-linked chart reviews while covering only half of Medicare Advantage enrollees. One top Medicare Advantage company, UnitedHealth Group (UNH), "stood out from its peers, especially in its use of in-home HRAs and HRA-linked chart reviews to generate risk-adjusted payments," according to the Office of Inspector General. Ohers involved include Alignment Healthcare (ALHC), Humana (HUM) and Cigna (CI), according to the agency. Reference Link

12:58 EDT Alpha Technology Group Ltd trading halted, volatility trading pause

12:56 EDT Southwest says expects continued cost pressure in Q4 - Says ratified all 12 of labor contracts. Says outlined a cost plan at Investor Day aimed at enhancing cost efficiency. Says expects savings to ramp over the next three years. Says received 19 Boeing aircraft, expects to receive one more. Says will pursue fleet monetization strategy with a focus on delivering a positive NPV. Says plan supports all 2027 targets without benefits of fleet monetization. Says expects $2.1B in capex this year. Says moderated capacity plan reduces need for new aircraft. Says Boeing production is something company is watching closely. Says has strong financial foundation and comprehensive, measurable plan.

12:48 EDT Southwest says serving more managed business customers 'than ever' - Says continuing to see increase of unique customers. Says continues to see opportunities to grow managed business. Says continues to extend ways of distribution in a 'low-cost' manner. Says red-eye schedule will be published next week.

12:36 EDT JetBlue launches service from Long Island MacArthur Airport - JetBlue announced it has officially launched service from Long Island MacArthur Airport, further expanding its footprint across New York. Starting Thursday, JetBlue is flying daily from Long Island to Orlando, and 4 times weekly to West Palm Beach and Fort Lauderdale. Long Islanders can now enjoy the signature JetBlue experience when flying to top vacation destinations without the commute. "We are delighted to bring the long-awaited JetBlue experience to Long Island," said Daniel Shurz, head of revenue, network, and enterprise planning at JetBlue. "These flights are a testament to JetBlue's loyal customer base on Long Island who have frequently traveled to New York's other airports to fly JetBlue. Customers no longer have to choose between the convenience of their local airport and the comfort, connectivity and customer service they enjoy with JetBlue."

12:04 EDT Community Health says increased denials 'relatively broad based' - On the company's earnings call, Community Health (CYH) executives stated in part, according to a transcript: "You know, we have been experiencing increased denials throughout the year as most of that claims activity is coming out of the prior year because, you know, there's quite a tail on the actual denial or appeal process. So what we saw in this quarter was an acceleration off of the run rate that we had in the first and second quarter. And that's the $10 million delta Kevin called out. It was that's the incremental increase that we did not expect that bounced in the third quarter." When asked in follow-up if this reflects broad based activity across most of payers, or if this is this more concentrated among a few, the company replied: "It's relatively broad based." Other publicly traded companies in the hospital space include HCA Healthcare (HCA), Tenet Healthcare (THC) and Universal Health (UHS).

12:00 EDT Celestica rises 18.6% - Celestica is up 18.6%, or $10.66 to $68.13.

12:00 EDT Molina Healthcare rises 23.4% - Molina Healthcare is up 23.4%, or $64.29 to $339.29.

12:00 EDT Community Health falls -23.2% - Community Health is down -23.2%, or -$1.29 to $4.26.

11:59 EDT U.K.'s CMA launches merger inquiry into Google's partnership with Anthropic - The U.K.'s Competition and Markets Authority announced that it is launching a formal investigation into Google's partnership with artificial intelligence startup Anthropic, saying it has "sufficient evidence" to launch a probe after it sought input earlier this year on whether the deal would stifle competition. The CMA has until December 19 to decide whether to approve the deal or escalate its investigation. Reference Link

11:32 EDT AbbVie, Gedeon Richter collaborate for discovery, development of novel targets - AbbVie and Gedeon Richter announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions. This collaboration expands upon the success of nearly two decades of partnership on central nervous system projects, including globally launched products such as cariprazine and the discovery of investigational drug candidate ABBV-932 for the treatment of bipolar depression and generalized anxiety disorder. Under the terms of the agreement, the collaboration includes both preclinical and clinical R&D activities with shared financing by the parties. Richter will receive an upfront cash payment of $25M, along with potential future development, regulatory and commercialization milestones. In addition, Richter may also receive sales-based royalties. AbbVie will have worldwide commercialization rights except for traditional markets of Richter, such as geographic Europe, Russia, other CIS countries and Vietnam.

10:59 EDT Treasury publishes final rule for Advanced Manufacturing Production Credit - The Internal Revenue Service and Department of the Treasury published a final rule that sets forth final regulations regarding the advanced manufacturing production credit established by the Inflation Reduction Act of 2022 to incentivize the production of eligible components within the United States. "Eligible components include certain solar energy components, wind energy components, inverters, qualifying battery components, and applicable critical minerals. These final regulations also address specific recordkeeping and reporting requirements. These final regulations affect eligible taxpayers who produce and sell eligible components and intend to claim the benefit of an advanced manufacturing production credit, including by making elective payment or credit transfer elections," Treasury stated in its rule document. Publicly traded companies in the solar energy space that may be impacted by the rule include Array Technologies (ARRY), Canadian Solar (CSIQ), Emeren (SOL), FTC Solar (FTCI), First Solar (FSLR), JinkoSolar (JKS), Maxeon Solar (MAXN), Shoals Technologies (SHLS), SolarEdge (SEDG) and SunPower (SPWR). Reference Link

10:00 EDT Molina Healthcare rises 21.1% - Molina Healthcare is up 21.1%, or $57.96 to $332.96.

10:00 EDT QuantumScape rises 25.8% - QuantumScape is up 25.8%, or $1.33 to $6.51.

10:00 EDT Community Health falls -20.5% - Community Health is down -20.5%, or -$1.14 to $4.42.

09:58 EDT Northrop Grumman says company backlog 'large, well-diversified' - Says International sales "rapidly expanding." Expects CapEx to come down in 2025, 2026 vs. prior levels.

09:51 EDT EU Court of Justice backs annulment of EUR 1.06B antitrust fine against Intel - The EU Court of Justice announced that it has upheld the annulment by the General Court of the Commission's decision finding an abuse of a dominant position on the part of Intel and imposing a fine of EUR 1.06B on Intel. In May 2009, the Commission imposed 1 a fine of EUR 1.06 billion on Intel, a microprocessor manufacturer established in the United States. The Commission complained that Intel had abused its dominant position on the market for x86 microprocessors by granting, inter alia, loyalty rebates to its customers and to a desktop computer distributor. In 2014, the General Court dismissed in its entirety Intel's action against that Commission decision. 2 On the appeal brought by Intel, the Court of Justice 3 set aside that judgment and referred the case back to the General Court. Hearing the case referred back to it, the General Court annulled the Commission's decision in part and annulled the fine of EUR 1.06 billion in its entirety. The Commission brought an appeal against the General Court's 2022 judgment. In its judgment, the Court of Justice rejects all of the grounds of appeal raised by the Commission. With regard to the as-efficient-competitor test, the Court of Justice confirms that it is for the General Court to examine any argument that is intended to call into question the Commission's assessments and that is capable of invalidating the conclusions reached by the Commission at the end of that test. Reference Link

09:48 EDT Wex falls -13.7% - Wex is down -13.7%, or -$29.09 to $183.95.

09:47 EDT West Pharmaceutical rises 15.2% - West Pharmaceutical is up 15.2%, or $43.56 to $330.00.

09:47 EDT SAG Holdings Ltd trading resumes

09:46 EDT Armlogi Holding Corp trading resumes

09:40 EDT GDEV Inc trading resumes

09:34 EDT Texas Instruments begins production of gallium nitride semiconductors in Japan - Texas Instruments announced it has begun production of gallium nitride-based power semiconductors at its factory in Aizu, Japan. Coupled with its existing GaN manufacturing in Dallas, Texas, TI will now internally manufacture four times more GaN-based power semiconductors, as Aizu ramps to production. "Building on more than a decade of expertise in GaN chip design and manufacturing, we have successfully qualified our 200mm GaN technology - the most scalable and cost-competitive way to manufacture GaN today - to start mass production in Aizu," said Mohammad Yunus, TI's senior vice president of Technology and Manufacturing. "This milestone enables us to manufacture more of our GaN chips internally as we grow our internal manufacturing to more than 95% by 2030, while also sourcing from multiple TI locations, ensuring a reliable supply of our entire GaN portfolio of high-power, energy-efficient semiconductors."

09:32 EDT CorroHealth enters agreements for investment from Patient Square Capital - CorroHealth signed definitive agreements for a strategic investment from Patient Square Capital. Current shareholders, including investment funds affiliated with global investment firm Carlyle, TT Capital Partners, Sanaka Group, and CorroHealth management, will remain investors, with Patient Square and Carlyle sharing joint control of CorroHealth. Carlyle has been the majority investor in CorroHealth since 2019 and a predecessor business since 2017. The transaction is expected to close by the end of the year.

09:31 EDT Armlogi Holding Corp trading halted, volatility trading pause

09:30 EDT GDEV Inc trading halted, volatility trading pause

09:26 EDT Tomi Environmental Solutions secures contract with Malaysian government - TOMI Environmental Solutions has secured a contract with the National Institute of Forensic Medicine in Malaysia. The agreement represents strategic progress as TOMI continues to expand its global footprint in critical environments and capitalizes on growing global demand. The contract involves the deployment of TOMI's newly launched SteraMist Integrated System - Standalone in the IPFN Biosafety Level 3 autopsy room.

09:22 EDT Wingstop named Official Chicken Partner of the NBA and NBA G League - Wingstop and The National Basketball Association, or NBA, announced a multiyear partnership making Wingstop the Official Chicken Partner of the NBA and NBA G League. The agreement marks Wingstop's first official partnership with a major U.S. professional sports league. The brand will leverage media exposure through virtual and courtside signage during nationally televised NBA broadcasts and will appear on the leagues' social and digital platforms throughout the season. As part of the partnership, Wingstop will have presence at NBA All-Star, beginning with NBA All-Star 2025 in the San Francisco Bay Area. The partnership builds on Wingstop's existing relationships with the NBA family, which include team partnerships with the Chicago Bulls, Detroit Pistons, Los Angeles Lakers, Milwaukee Bucks and New York Knicks.

09:21 EDT Cyclacel Pharmaceuticals granted extension for regain Nasdaq compliance - Cyclacel Pharmaceuticals received a written notice from The Nasdaq Stock Market granting the Company an extension until December 24, 2024, to regain compliance with Nasdaq's minimum stockholders equity requirement under Nasdaq Listing Rule 5550(b)(1). This Notice has no immediate effect on the listing of the Company's common stock on Nasdaq. As previously reported, on August 26, 2024, the Listing Qualifications Staff of Nasdaq determined that the Company was not in compliance with the Equity Standard Rule because the Company reported stockholders' equity of less than $2.5 million as of June 30, 2024.

09:17 EDT UPS CEO says will give outlook on 2025 after getting through Q4

09:14 EDT Lexaria announces partial 12-week blood sugar results from GLP-1 diabetes study - Lexaria Bioscience received partial 12-week blood sugar results from the recently completed animal study WEIGHT-A24-1. The company said, "Lexaria is strongly encouraged that the DehydraTECH-liraglutide and DehydraTECH-CBD groups A and B outperformed all three of the Rybelsus and pure semaglutide DehydraTECH composition groups regardless of whether the semaglutide had or had not been processed with the salcaprozate sodium technology known as "SNAC". Rybelsus, which utilizes Novo Nordisk's proprietary SNAC technology, is the world's only orally administered GLP-1 drug brand. Study data for four additional animal groups, including a positive control group of Rybelsus that has not been processed with DehydraTECH, will be available soon. Of the eight Study groups reported on today, DehydraTECH-CBD group B and the sole DehydraTECH-liraglutide group H were both successful in reducing blood sugar levels, while the other six groups, including all three of the Rybelsus and pure semaglutide DehydraTECH composition groups, were not. This Study is the world's first to evaluate the relative performance of liraglutide processed with DehydraTECH. Thus, the outperformance of DehydraTECH-liraglutide compared to the other groups is of notable interest and was unexpected. In this Study, the processed liraglutide in Study group H was administered orally even though it is injected when used by patients under the brand names Saxenda or Victoza."

09:12 EDT Northrop Grumman sees International sales growing faster than rest of business - Expects solid growth, strong performance to continue in 2025. Sees "reduced" CapEx in 2025. Comments taken from Q3 earnings conference call.

09:11 EDT MoneyHero appoints Pai to its board of directors - MoneyHero announced that Wallace Pai has been named to the company's board of directors, effective immediately. In connection with his appointment, Pai has also replaced MoneyHero's Chairman, Kenneth Chan, on the Company's Audit Committee, ensuring the Committee is comprised entirely of Independent Non-Executive Directors.

09:10 EDT ImmunityBio: 1st patient dosed in CAR-NK cell therapy study relapsed NHL - Immunotherapy innovator ImmunityBio announced that the first patients have been dosed in an initial trial studying the potential of the company's CAR-NK cell therapy targeting CD-19 in the treatment of non-Hodgkin's lymphoma NHL . In the QUILT 106 trial, CD19-targeted high-affinity natural killer or t-haNK cells are being tested initially as a single agent, and after demonstrating safety, then in combination with standard NHL treatment rituximab, in participants with selected CD19+ and CD20+ relapsed/refractory B-cell NHL. The phase 1, open label clinical study is designed to enroll up to 10 participants and is being conducted in Johannesburg, Pretoria, and Bloemfontein, South Africa. This is the first cellular-targeted natural killer NK cell therapy study ever to be conducted in South Africa, and is designed to provide important clinical information on a cancer with a significant rate of diagnosis in the region, but with few treatment options. Non-Hodgkin's lymphoma is the 6th most common malignancy among people in Sub-Saharan Africa and it is the 4th most diagnosed cancer in men and the 5th most diagnosed cancer in women in South Africa, according to the Cancer Association of South Africa. "This trial is important for ImmunityBio as our first clinical study of our CAR-NK, CD19 t-haNK cell line, as well as one of our first studies in liquid tumors," said Patrick Soon-Shiong, M.D., Executive Chairman, Founder and Global Chief Scientific and Medical Officer at ImmunityBio. "We have chosen to undertake this trial because Sub-Saharan African and, in particular, South African populations are often overlooked when it comes to advanced clinical research, despite the need for innovative immunotherapies in the region."

09:09 EDT Nephros launches HydraGuard 20" UltraFilter - Nephros announced the release of the HydraGuard 20" UltraFilter. This latest innovation enables the company to break into new markets and aid in compliance with water quality standards such as ANSI/AAMI ST108. The HydraGuard 20" model is an extension of the existing HydraGuard and designed to provide a higher-volume capacity and flow rate, while removing harmful contaminants like bacteria, viruses, and endotoxins. With this product, Nephros is poised to serve a broader range of customers, including companies within medical device manufacturing and pharmaceutical production, to ensure the highest level of water purity for industries that require strict quality standards.

09:09 EDT Abbott initiates clinical trial of its CardioMems in advanced heart failure - Abbott announced a new, first-of-its-kind clinical trial designed to improve outcomes in patients with worsening heart failure who could benefit from advanced therapy options. The TEAM-HF trial, which is planned to enroll up to 850 patients across 75 sites worldwide, will measure pulmonary artery pressures - PAP - using Abbott's CardioMEMS HF System to objectively identify advanced heart failure patients at high risk of mortality who could benefit from a life-saving HeartMate 3 left ventricular assist device earlier in their disease progression. The TEAM-HF trial will deploy a novel approach to assess the impact of earlier interventions in patients with worsening heart failure. The CardioMEMS sensor, placed in the pulmonary artery during a minimally invasive outpatient procedure, monitors pulmonary artery pressure changes over time. If pressures do not go down with guideline directed medical therapy, the TEAM-HF trial will seek to prove that such patients will benefit from advanced therapies. Enrollment in TEAM-HF will commence shortly at sites across the U.S. The trial's powered primary and secondary endpoints will be evaluated at two years, with long-term follow up through five years.

09:08 EDT Verizon launches Verizon Family app - Verizon announced the launch of a brand new app, Verizon Family, a digital service that helps families stay connected and safe. The company said, "With Verizon Family, you can monitor your family's location, set up new features, like Safe Walk with an SOS button to contact a family member in an emergency, and even keep an eye on your children's Verizon calls and texts."

09:07 EDT NAYA Biosciences initiates Phase 1/2a trial for NY-303 - NAYA Biosciences announced an update regarding its clinic trial plans. The Company received regulatory approval from the Israeli Ministry of Health in July 2024 and subsequent institutional review board clearance to initiate patient enrollment in up to 7 academic centers for its clinical trial evaluating the safety and efficacy of NY-303, its GPC3-targeting NK Engager bispecific antibody, as a monotherapy for the treatment of hepatocellular carcinoma in patients not responding to first-line immunotherapy.

09:05 EDT Clearfield CMO Kevin Morgan switches to advisor role, Anis Khemakhem to succeed - Clearfield announced a strategic leadership transition, appointing Anis Khemakhem as chief marketing officer, or CMO, effective January 1, 2025. Khemakhem, who joined Clearfield earlier this year as VP of global technology platforms, brings with him over 25 years of industry experience, with diverse leadership skills. Kevin Morgan, who has served as Clearfield's CMO since 2016, will transition into the newly created role of executive advisor to the CEO. In this role, Morgan will maintain Clearfield's connection with the Fiber Broadband Association, supporting public policy efforts while also representing Clearfield at select industry conferences and authoring articles for publications.

09:05 EDT Franklin Access announces updates to JEXtream MDM platform - Franklin Access unveils significant enhancements to its JEXtream Mobile Device Management, MDM, platform, reinforcing its commitment to providing versatile solutions for enterprise clients and educational institutions. OC Kim, CEO of Franklin Access, states, "These enhancements to JEXtream MDM demonstrate our commitment to evolving our platform to meet diverse needs. We're providing our clients with advanced tools for efficient and secure device management in today's dynamic digital landscape whether it be for enterprise or educational purposes."

09:03 EDT Precision BioSciences receives CTA approval in Moldova for PBGENE-HBV - Precision BioSciences announced that it has received clinical trial application, or CTA, approval in Moldova for its lead candidate, PBGENE-HBV. PBGENE-HBV is Precision's wholly owned in vivo gene editing program designed to cure chronic hepatitis B by eliminating cccDNA, the key source of replicating hepatitis B virus, while also inactivating integrated HBV DNA in hepatocytes. The company has opened the Phase 1 clinical program and is moving towards dosing patients.

09:02 EDT Acuity Brands announces agreement to acquire QSC for $1.215B - Acuity Brands has reached a definitive agreement to acquire QSC for a purchase price of $1.215B, or $1.1B net of approximately $100M in present value of expected tax benefits. The net purchase price represents approximately 14 times QSC's estimated EBITDA for the last twelve months ending August 31, 2024. It is expected to be accretive to Acuity's' fiscal 2025 full-year adjusted diluted earnings per share. "We are excited to be joining a company that is aligned around our long-term mission and shares our values," said Joe Pham, Chairman and Chief Executive Officer of QSC. "Our shared vision of how we can leverage data with our technology solutions will elevate our ability to service our end-users and drive growth."

09:01 EDT UPS CEO says seeing 'real good uptake,' keep rate on holiday peak surcharge

08:59 EDT Phunware CEO Mike Snavely retires, Stephen Chen named interim - Phunware announced that Michael Snavely, CEO of Phunware, has retired and resigned from Phunware. Stephen Chen, former Chairperson of the Phunware Board of Directors, has assumed the role of interim CEO of Phunware, effective October 22, 2024.

08:58 EDT LPL Financial: Dougherty, Tedesco joins broker-dealer, RIA, custodial platforms - LPL Financial announced that the financial advisors at Dougherty, Tedesco & Associates have joined LPL Financial's broker-dealer, RIA and custodial platforms. They reported serving approximately $800 million in advisory, brokerage and retirement plan assets, and join LPL from Osaic. Founded in the early 1980s by Charlotte Dougherty, the business has evolved over the years to into a holistic wealth management firm and cornerstone of the greater Cincinnati area. Now under the leadership of advisors Andrew Tedesco, and John Dougherty, III, the firm offers a comprehensive range of wealth advisory services, including financial planning, investment management, retirement planning and estate planning. The team also includes Registered Sales Assistant John Dougherty, Jr., Director of Client Services Caitlin Ackerman and support staff members Rita Anno and Ben Verchick.

08:56 EDT Nexa Resources reports Q3 exploration results - Nexa Resources provided the drilling and assay results from the third quarter of 2024. Nexa's 2024 drilling strategy emphasizes near-mine expansion and brownfield and infill drilling, with additional exploration drilling planned for promising greenfield projects. Exploration expenditure and drilling execution are approximately 14% behind schedule, mainly due to operational challenges and rainfall impacting activities at Cerro Lindo. By the end of the third quarter, cumulative drilling reached 170,008 meters comprising 44,658 meters from exploration drilling and 125,350 meters from mining infill drilling. Total exploration drilling for 3Q24 amounted to 18,850 meters, with 11,391 meters completed in Peru, 6,712 meters in Brazil, and 746 meters in Namibia. This includes 5,193 meters dedicated to early-stage greenfield projects in Brazil and Peru. Drilling activities in 3Q24 were behind schedule, primarily due to technical and mechanical issues affecting early-stage greenfield projects in Brazil, Peru, and Namibia, resulting in of 2,496 meters less drilling than was planned. For the next quarter, planned exploration drilling includes 13,475 meters in Peru, 5,350 meters in Brazil, and 1,450 meters in Namibia, totaling 20,275 meters. Highlights: Cerro Lindo, Orebody 8B: 4.6 meters at 2.75% Zn and 0.47% Cu in drill hole PECLD07556 from 544.95 meters. Aripuana, Massaranduba target: 4.1 meters at 0,61% Cu in drill hole BRAPD000198 from 651.4 meters. Vazante, Sucuri Norte orebody: 3.3 meters at 7.13% Zn in drill hole BRBVZEND000067 from 469.0 meters. El Porvenir, Integracion target: 19.2 meters at 4.53% Zn in drill hole PEEPD02781 from 297.9 meters;5.5 meters at 5.84% Zn and 1.58% Cu in drill hole PEEPD02802 from 452.8 meters. 14.4 meters at 4.02% Zn and 0.50% Cu in drill hole PEEPD02802 from 501.0 meters. Commenting on the report, Jones Belther, Senior Vice President of Mineral Exploration & Business Development, said "Our brownfield exploration programs are progressing well, focused on expanding our exploration portfolio and extending the life of our mines. At Cerro Lindo, drilling has confirmed the depth and continuity of mineralization in Orebody 8B. At Aripuana, recent exploration of the Massaranduba target, located 3 km southeast of Babacu, identified mineralized intercepts. Results at Vazante confirm the extent of mineralization at the northern end of the Sucuri target. Meanwhile, at our Pasco complex, drilling continues to expand the depth of mineralization at the Integracion orebody."

08:54 EDT Peraso secures $1.4M follow-on order from South African WISP - Peraso announced a $1.4 million follow-on purchase order from a prominent South African wireless Internet service provider. This order for Peraso's innovative mmWave equipment builds on an initial production order secured and shipped in the second quarter of 2024.

08:53 EDT Tractor Supply reports Q3 SSS down 0.2%

08:52 EDT Sezzle partners with Shoplazza to offer flexible payment options to merchants - Sezzle announce a new partnership with Shoplazza, an e-commerce platform. This collaboration will enable thousands of Shoplazza merchants doing business in the US to offer flexible payment options through Sezzle, enhancing the shopping experience for their customers and providing significant business growth opportunities for merchants.

08:51 EDT Pineapple Energy subsidiary completes engineering work on 8.46MW installations - SUNation, the subsidiary of Pineapple Energy, has completed the foundational engineering work for an 8.46 MW series of commercial projects on Long Island collectively valued at $11 million. The work was performed as part of an exclusive Letter of Intent on the engineering portion of the project. SUNation is working with the project principals to finalize details for contracts that would have the Company perform installation of photovoltaic modules and racking systems across their various sites. Any future work agreed upon via letters of intent between the two parties is non-binding and subject to normal closing conditions.

08:49 EDT Chromocell Therapeutics announces amendment to stock repurchase plan - Chromocell Therapeutics board of directors has authorized an amendment to the Company's existing stock repurchase plan to increase the total value of shares of Chromocell's common stock available for repurchase by the Company under the Repurchase Plan by an additional $500,000, to $750,000. In addition, the Amendment extends the termination date of the Repurchase Plan from December 31, 2024 to June 30, 2025. The Repurchase Plan does not obligate the Company to acquire any particular amount of Common Stock, and it may be modified, extended or terminated by the Board of Directors at any time.

08:48 EDT GRI Bio raises $13.9M in gross proceeds since start of 2024 - GRI Bio announced that on October 22, 2024 it closed its previously announced transaction involving the exercise of certain existing warrants to purchase an aggregate of 762,236 shares of the Company's common stock originally issued by GRI Bio in February 2024. The gross proceeds to the Company from the exercise of warrants were approximately $0.8 million, prior to deducting placement agent fees and offering expenses payable by the Company. Including the gross proceeds from this offering, the Company has raised approximately $13.9 million in gross proceeds since the beginning of 2024. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. Marc Hertz, PhD, Chief Executive Officer of GRI Bio, commented, "The proceeds from the financings we have completed since the start of this year have greatly strengthened our balance sheet and are estimated to have provided the necessary funding to advance the development of our lead program into the middle of the first quarter of 2025. With these proceeds in hand and the continued progress toward interim and topline data for our lead program, expected in the coming quarters, we believe we are well positioned to realize the full potential of GRI-0621 to provide significant benefit to IPF patients."

08:46 EDT ConnectM launches AI-driven heat pump following AHRI Cold Climate Certification - ConnectM Technology Solutions announced its AI-powered heat pump has received the prestigious AHRI Cold Climate Certification, representing a significant milestone in energy-efficient heating solutions. This certification follows the previously announced launch and underscores ConnectM's commitment to delivering state-of-the-art technology that meets the highest standards for performance in even the harshest of winter conditions.

08:45 EDT American Airlines sees 2025 capacity up low single digits y/y

08:44 EDT CorMedix announces new data at ASN Kidney Week 2024 - CorMedix announced new hospital admission and health economic data presented at the American Society of Nephrology Kidney Week 2024 in San Diego, CA from October 24 - 27. This retrospective analysis, using data from the Premier Healthcare Database, evaluated hospital admissions from 2020 to 2022 to examine the demographics, clinical characteristics, and outcomes of adult HD-CVC patients hospitalized for bloodstream infections. Key findings include: The patient population was 58.2% white, 27.1% black, and 56.6% male, with 59.3% aged 60 years or older. The median length of stay for BSI-related hospitalizations was 16 days, with 53.8% of admissions involving time in the ICU. The study reported an all-cause in-hospital mortality rate of 10.3%. Patients had extensive comorbidities, with 87.8% having three or more Charlson comorbidity conditions, and 42.6% had six or more. The median total cost of admission was $157,000, with $65,000 attributed to ICU care alone. Healthcare utilization, including readmissions, placed a significant financial burden resulting from these infections.

08:44 EDT American Airlines expects to recover lost corporate sales by end of 2025

08:44 EDT UPS CEO says shippers have recently 'tempered' holiday expectations

08:43 EDT Inspira Technologies appoints Glo-Med as primary U.S. distributor - Inspira Technologies has entered into an agreement with Glo-Med Networks , which will serve as Inspira's primary distributor in the U.S. Glo-Med's distribution facility will serve as a support center for the deployment of the INSPIRA ART100 in the U.S. The INSPIRA ART100 is FDA 510(k)-cleared for Cardiopulmonary Bypass procedures. Toward the planned deployment of the INSPIRA ART100 in 2024 and looking ahead, the company's goal is to introduce physicians and perfusionists to Inspira's technologies and brand proposition in preparation for the future planned deployment of the flagship INSPIRA ART. The distribution facility, located in Florida, will potentially facilitate the commercialization of additional products in the U.S. market in the future. The medical distribution and service facility will be fully operated by Glo-Med and will serve as a central hub for Inspira's logistics operations. Additionally, the facility will provide original equipment manufacturer certified after-market services through a partnership with Med-Stat Consulting Services), a national biomedical engineering services firm founded in 2003.

08:42 EDT Honeywell expects organic growth at 'upper end' of long-term target - Says will pursue "bolt-on" M&A. Says operational environment is "challenging." Says lack of short cycle improvement and some supply chain disruption in September in Aerospace caused the company to rebase full year expectations. Comments taken from Q3 earnings conference call.

08:42 EDT Regeneron, Sanofi announce presentation of Dupixent Phase 3 data in CSU - Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) will present data from the Phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent in biologic-naive patients with uncontrolled chronic spontaneous urticaria who receive background therapy with antihistamines. Results showed treatment with Dupixent significantly reduced itch and urticaria activity scores from baseline, and a higher proportion of patients achieved well-controlled disease status compared to placebo. The data are being shared in a late-breaking oral presentation at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting in Boston, Massachusetts. Study C enrolled 151 children and adults who were randomized to receive Dupixent or placebo added to standard-of-care histamine-1 antihistamines. At 24 weeks, Dupixent demonstrated significant improvements compared to placebo on: Itch severity score; Urticaria activity score; Well-controlled disease status; Complete response. The safety results in Study C were generally consistent with the known safety profile of Dupixent in its approved dermatological indications. Overall rates of treatment emergent adverse events were 53% for both Dupixent and placebo. AEs more commonly observed with Dupixent compared to placebo included injection site reactions, accidental overdose and COVID-19 infection. Dupixent has been approved for CSU in Japan and the United Arab Emirates and is also under regulatory review in the European Union based on earlier trial readouts. Outside of Japan and the UAE, the safety and efficacy of Dupixent for CSU has not been fully evaluated by any regulatory authority.

08:40 EDT CLPS declares special cash dividend of 13c per share - CLPS declared a special cash dividend of 13c per share of common stock, payable on November 12 to shareholders of record as of November 4. The aggregate amount of the payment to be made in connection with this special cash dividend will be approximately $3.6M.

08:40 EDT Metagenomi presents poster on genome editing at ESGCT - Metagenomi presented a poster titled "Efficient and specific genome editing with metagenomics-derived base editor for human therapeutic applications" at the European Society of Gene and Cell Therapy, ESGCT, 31st Annual Congress in Rome, Italy. The poster presentation described the following key advantages of the Metagenomi ABE platform: Targetability: Metagenomi's ABE is targetable to over 95% of the human genome's base pairs, a significantly wider range of sites than first-generation SpCas9 base editors. Efficiency: The ABE platform achieved over 95% reproducible and durable triplex protein knockdown in primary T-cells, confirming its highly efficient application for multiplex gene editing. Specificity: The ABE demonstrated highly specific on-target deamination with minimum-to-no indel formation. Genome-wide analyses confirmed no detectable translocations and no significant genomic composition differences when compared to unedited cells. Tolerability: Metagenomi's ABE triplex protein knockdowns exhibited excellent tolerability in cells, with no adverse effects on cell viability, expansion, or changes in stress-related gene expression observed post-editing.

08:39 EDT Skyharbour announces ANT survey prior to upcoming fall drill program - Skyharbour Resources has carried out an Ambient Noise Tomography survey prior to the upcoming fall drill program, and has received the remaining results from the second phase of the program earlier this year at the 73,294 hectare Russell Lake Uranium Project. The Project is 51% owned by Skyharbour as operator, with joint-venture partner Rio Tinto Exploration Canada owning the other 49%. It is strategically located in the central core of the Eastern Athabasca Basin of northern Saskatchewan adjacent to regional infrastructure, including an all-weather road and powerline, allowing for drilling throughout all seasons. In preparation for the upcoming drill program at Russell, Skyharbour has completed an Ambient Noise Tomography survey at the Russell Lake Project. The survey used Fleet Space Technologies' ExoSphere technology to acquire 3D passive seismic velocity data over the highly prospective Grayling and Fork target areas, where previous drilling has intersected high-grade uranium mineralization. The ANT technology has been successfully employed in mapping significant sandstone and basement structures and associated alteration zones related to hydrothermal fluids pathways in the Athabasca Basin. The results from this survey will be used to further refine drill targets for the fall 2024 drill program at Russell. Skyharbour is fully funded and permitted for the follow-up fall drill campaign consisting of approximately 7,000 metres of drilling at its main Russell and Moore Projects, with 2,500 metres of drilling at Moore and 4,500 metres of drilling at Russell. Drilling at Russell earlier this year was completed during two separate phases of drilling, with a total of 5,152 metres drilled in ten holes during the winter and spring of 2024. The first phase of drilling consisted of a total of 3,094 metres in six holes, which was previously reported, while the second phase of drilling consisted of 2,058 metres of drilling in four holes. During Phase One, the best intercept of uranium mineralization to date on the property was intersected in RSL24-02, which returned a 2.5-metre-wide intercept of 0.721% U3O8 at a relatively shallow depth of 338.1 metres, including 2.99% U3O8 over 0.5 metres at 339.6 metres, just above the unconformity in the sandstone. The mineralization is open in all directions and will be a focus of upcoming drilling. Phase Two drilling at the MZE target, approximately 10 km northeast of the Fork target, identified prospective faulted graphitic gneiss accompanied by anomalous sandstone and basement geochemistry. All processing of the core has been completed, and geochemical results have now been obtained for all drill holes.

08:39 EDT Intellia Therapeutics presents results from Phase 2 study of NTLA-2002 - Intellia Therapeutics announced positive Phase 2 data from the ongoing Phase 1/2 study of NTLA-2002 in patients with hereditary angioedema, HAE, with results continuing to indicate that NTLA-2002 has the potential to eliminate HAE attacks following a one-time infusion. Results were published online today in The New England Journal of Medicine and will be presented on Saturday, October 26 at the 2024 American College of Allergy, Asthma & Immunology, ACAAI, Scientific Meeting in Boston, Massachusetts. Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16, respectively. Eight of 11 patients in the 50 mg arm were completely attack free following a one-time infusion through the latest follow-up; data support NTLA-2002's potential to be a functional cure for hereditary angioedema.

08:37 EDT Farmmi unit enters cooperation agreement with Mazon Technology - Farmmi announced that the company's subsidiary, Farmmi USA, has reached an agreement in principle with Mazon Technology for strategic cooperation in warehousing and logistics services that could potentially bring in $10M in annual orders for Farmmi USA. The company considers it a new major operational development for Farmmi USA since the launch of the trial operation of the company's warehousing logistics base in California in August.

08:35 EDT UPS says Q3 macro environment 'slightly worse than expected' - UPS Chief Executive Officer Carol Tome is speaking at the start of the company's earnings call.

08:33 EDT Innovative Eyewear gets notice of patent allowance for smart eyewear technology - Innovative Eyewear received on October 23rd, a notice of allowance for its utility patent application U.S. Patent Application No. 17/104,849, entitled "Wireless Smartglasses with Quick Connect Front Frames". After paying the required issue fee, the company anticipates that a patent will issue in due course. The patent is directed to smartglasses that pair or connect with other mobile devices and have removable front frames connected with a quick-disconnect hinge, which allows end users to customize their glasses after purchase with a variety of lens types and frontplate styles.

08:32 EDT Allison Transmission expanding manufacturing facility in India - Allison Transmission is pleased to announce the expansion of its state-of-the-art manufacturing facility in Chennai, India, to support increasing global demand for Allison fully automatic transmissions. The multi-year, over $100M investment will double the existing manufacturing footprint of the Chennai facility. The expansion will increase production capacity for Allison's on-highway fully automatic transmission portfolio, enhancing global operational flexibility and capability. Allison continues to invest in its business in order to achieve its growth ambitions and deliver its brand promise to Improve the Way the World Works.

08:30 EDT Enviri's Harsco secures 10-year contract with Nucor Steel - Harsco Environmental, a division of Enviri Corporation, announced that it has signed a 10-year services contract with Nucor Steel Kingman in Arizona, a leading manufacturer of steel and steel products. "Harsco Environmental is pleased to partner with Nucor Steel Kingman," stated Harsco Environmental Regional President of North America, Joe Burkey. "This contract is a testament to our commitment to safety and sustainability, and we are proud to be a technology partner providing Nucor with economically viable solutions for the treatment and reuse of their production co-products."

08:28 EDT Bayer enters licensing agreement with Dewpoint Therapeutics - Bayer has entered into an exclusive licensing agreement with Dewpoint Therapeutics for a heart disease program to treat dilated cardiomyopathy patients, who are characterized through carrying specific mutations. This is the first option exercise under the research collaboration between Bayer and Dewpoint Therapeutics, Inc., which began in November 2019.It leverages Dewpoint's proprietary platform for biomolecular condensates and Bayer's small molecule R&D capabilities to develop new treatments for cardiovascular and renal diseases. Dilated cardiomyopathy is a heart muscle disease where the ventricles enlarge and struggle to pump blood effectively. The licensed program focuses on an innovative method to address a specific form of DCM linked to mutations that lead to the formation of disease-associated condensates. This form of DCM is a severe condition with significant unmet medical needs, characterized by early onset heart failure and frequent life-threatening arrhythmias. Dewpoint Therapeutics will receive an upfront and additional development and commercial milestone payments amounting to an estimated $424 million, excluding royalties. The ongoing collaboration follows Bayer's participation in Dewpoint's January 2019 Series A financing round through Leaps by Bayer, the strategic investment unit of Bayer.

08:27 EDT Envoy Medical supports ITEM Coalition letter to CMS on hearing devices - Envoy Medical expresses gratitude to the Independence Through Enhancement of Medicare and Medicaid Coalition and the twelve ITEM member signatories for sending a strong letter to CMS supporting a reconsideration of the benefit category for fully implanted active middle ear hearing devices. The letter states in part: "[W]e request that you please provide an explanation as to CMS' reasoning for determining that fully implanted active middle ear hearing devices do not qualify as an exception to the hearing aid exclusion under statute. In addition, we believe CMS has the authority to reconsider their decision and urge you to clarify that this technology qualifies as a prosthetic device for purposes of Medicare coverage." ITEM is a national consumer- and clinician-led coalition advocating for access to and coverage of assistive devices, technologies, and related services for people with injuries, illnesses, disabilities, and chronic conditions of all ages. Members represent individuals with a wide range of disabling conditions, as well as the providers who serve them. In the letter to CMS, ITEM referenced the profound impact that hearing loss has on quality of life of Medicare beneficiaries. The Hearing Loss Association of America and Alexander Graham Bell Association for the Deaf and Hard of Hearing were two of the twelve organizations willing to lend their voice and influence to the Medicare beneficiaries with significant hearing loss who want access to novel hearing implants. "We are grateful that the ITEM Coalition took up such a critically important issue and that twelve coalition member organizations signed the letter urging CMS to do the right thing," commented Brent Lucas, Envoy Medical CEO. "It especially hits home that the Coalition's mission is in their name -- 'Independence Through Enhancement of Medicare and Medicaid' - and we strongly believe that fully implanted hearing devices can help Medicare beneficiaries with hearing impairments significantly regain, or maintain, a level of independence that is good for them and for society as a whole."

08:24 EDT Bionano Genomics announces publication outlining utility of OGM - Bionano Genomics announced the publication in Blood Cancer Journal by a group of researchers at the Korea College of Medicine in South Korea showing that optical genome mapping can resolve rearrangements in the MYC gene in multiple myeloma, which represent highly actionable biomarkers in cancer. MM accounts for 1.3% of all malignancies and 12% of all hematologic cancers. Among the hallmark genetic abnormalities in MM are rearrangements involving the MYC gene, a potent oncogene which encodes a protein that functions as a transcriptional regulator. The release of compelling data in MM underscores the potential for wider adoption and use of OGM across all blood cancers as an alternative to traditional methods like karyotyping and fluorescence in-situ hybridization. Key findings: OGM performed better than conventional cytogenetics: Using OGM, the results were MYC-positive in 40% of cases, while positive rate was 26% and 13% using FISH and karyotype, respectively. Karyotyping can fail to identify MYC rearrangements and cannot resolve its translocation partners, which is a critical component in the stratification of the disease for prognosis and management. Complementary to other molecular techniques: OGM provides a complementary approach by revealing large structural variations that may be missed by methods like next-generation sequencing. A comprehensive view of genome variation can provide a more complete understanding of the drivers of multiple myeloma, which could lead to advancements of precision medicine. Streamlined Workflow and Cost Efficiency: The study also highlights the efficiency of OGM compared to traditional cytogenetics, which can be time consuming and laborious. OGM can reduce the need for sequential analysis such as karyotyping, followed by multiple rounds of FISH analysis. OGM can provide the same information and more in a single assay versus the tiered assays, and shorten the time to accurate classification and stratification of blood cancers, including MM.

08:23 EDT The Marygold Companies acquires 7.95% stake in MCHC - The Marygold Companies announced it has acquired a 7.95% ownership position, investing $1.8M in Delaware based Midland Capital Holdings Corporation MCHC a privately owned holding company whose principal operating entity is Midland Federal Savings and Loan Association or Midland Federal, headquartered in Bridgeview, Illinois. Operating continuously in the greater Chicago area since 1914, Midland Federal has total assets of approximately $115M , with four full-service branch offices-two in Chicago, and in nearby Bridgeview and Homer Glen, Illinois. As part of the transaction, TMC also holds 180,044 warrants to purchase 180,044 additional shares of MCHC at an exercise price of $22.25. The warrants expire on February 27, 2034. "The transaction affirms our corporate strategy and focus on the financial services and fintech sector," said Nicholas Gerber, CEO of TMC. "It follows our recent acquisitions of UK-based investment advisory firms Tiger Financial & Asset Management and Step By Step Financial Planners, which are now wholly owned TMC indirect subsidiaries, plus our long-established ETF management subsidiary, USCF Investments, with approximately $3.2B in assets under management.

08:19 EDT Prime Medicine presents data from multiple studies showcasing LNP platform - Prime Medicine presented data from multiple studies showcasing the potential of its proprietary, universal lipid nanoparticle, LNP, platform to precisely deliver Prime Editors to correct disease-causing mutations in the liver. The in vivo proof-of-concept data shared at the European Society of Gene and Cell Therapy, ESGCT, 31st Annual Congress demonstrated successful correction of disease-causing mutations in Wilson's Disease in both mouse and non-human primate, NHP, models. Additionally, the Company highlighted the ability of its universal liver-targeted LNP platform to deliver Prime Editors to correct the underlying mutational cause of Glycogen Storage Disease Type 1b, GSD1b, in humanized mice and NHPs, reinforcing the potential for its modular LNP to support future programs in rare and non-rare liver indications.

08:17 EDT Integer names Payman Khales COO, Andrew Senn president, Cardio & Vascular - Integer Holdings announced that Payman Khales will assume the newly created role of COO during the first quarter of 2025. Andrew Senn will take Mr. Khales' place as the President, Cardio & Vascular at the same time. Khales joined the Company in early 2018 and has served as the President, Cardio & Vascular. Under his leadership, this business has accelerated its sales and market penetration and achieved above-market growth. As Integer's COO, Khales will oversee both of Integer's product categories along with Global Operations and Manufacturing Strategy. Senn has been with Integer for eighteen years, including fifteen years in our Cardio & Vascular product category, and his most recent executive role has been Senior Vice President, Strategy, Business Development, and Investor Relations.

08:14 EDT Oracle-s Alloy selected by NTT DATA Japan for cloud services - Oracle announced that NTT DATA Japan, a global digital business and IT services leader that is part of the NTT Group, has selected Oracle Alloy to help Japanese organizations across the public and private sector accelerate the use of cloud services while addressing data sovereignty and compliance requirements. With Oracle Alloy deployed in its data centers, NTT DATA Japan will be able to give its customers access to 150+ Oracle Cloud Infrastructure services, including the latest AI capabilities. Oracle Alloy is a complete cloud infrastructure platform that enables Oracle partners to become cloud service providers. Additional capabilities powered by Oracle Alloy are scheduled to be available on OpenCanvas in the Japan East region by the end of December 2025 and in the Japan West region by the end of March 2027. OpenCanvas will also continue to provide its own customized, proprietary cloud services.

08:12 EDT Apogee Therapeutics announces updated results from Phase 1 trial of APG777 - Apogee Therapeutics announced updated positive results from its ongoing Phase 1 clinical trial of APG777, a novel half-life extended anti-IL-13 antibody for the treatment for atopic dermatitis and other inflammatory diseases, in healthy volunteers up to nine months. These data will be presented at the American College of Allergy, Asthma & Immunology's, ACAAI, 2024 Annual Scientific Meeting, held in Boston from October 24-28, 2024. Key Findings from the Phase 1 APG777 Results Up to 9 Months: Dose proportional PK was observed, with a half-life of ~75 days, approximately three to five times that of currently approved treatments for moderate-to-severe AD consistent with previously reported interim results; APG777 demonstrated dose proportional increases in Cmax and AUC from 300mg up to 1,200mg across all SAD and MAD cohorts. Single and multiple doses of APG777 resulted in rapid and sustained effect on PD markers for up to nine months; Single doses of APG777 showed rapid, near-complete inhibition of pSTAT6, one of the first downstream markers of IL-13 pathway inhibition, up to nine months; MAD cohorts showed similar inhibition of pSTAT6 through available follow-up. APG777 was generally well-tolerated at doses up to 1,200 mg; Treatment-emergent adverse events were generally mild-to-moderate and unrelated to APG777; there were no serious adverse events or dose-dependent trends observed up to time of data cut

08:11 EDT Takeda and BMC team on decarbonization across health care ecosystem - Takeda and Boston Medical Center BMC announced a new collaboration focused on identifying innovative solutions that can reduce hard-to-abate greenhouse gas GHG emissions in the health care sector. The collaboration between Takeda and BMC aims to reduce the GHG emissions caused by disposal of regulated medical waste, such as pharmaceutical packaging and single-use plastics, which are among the most difficult environmental challenges facing the industry. The effort will also seek to scale the interventions developed through the collaboration by sharing best practices to help other organizations adopt and learn new ways to decarbonize in their operations to drive wider health care ecosystem impact...As a part of this collaboration, Boston Medical Center will conduct waste audits across key clinical areas to identify emission hotspots and pilot new technologies aimed at reducing emissions from the disposal of regulated medical waste, including pharmaceutical packaging. BMC, recognized with multiple Practice Greenhealth Top 25 Environmental Excellence Awards, is the first hospital in the nation to leverage a rooftop solar array to provide energy bill credit to eligible patients facing energy insecurity...For Takeda, this collaboration supports its ambitious climate goal to reach net-zero greenhouse gas GHG emissions in its operations by 2035 and across our value chain by 2040. In 2024, the Science Based Targets initiative SBTi validated Takeda's net zero GHG emission goals as being consistent with reductions required to limit the rise in global temperature to 1.5 degrees C above pre-industrial levels.

08:11 EDT ABM, Mainspring Energy sign strategic partnership - ABM announced a strategic partnership with Mainspring Energy, in which ABM will deploy Mainspring's cutting-edge Linear Generator technology to enhance electric vehicle charging solutions for fleet, commercial and industrial clients that require turnkey offerings and on-site power generation projects.

08:09 EDT Movano plans Response Submission to FDA for EvieMed final review - Movano plans to submit updated responses next week to all clarifying questions that it recently received from the FDA as part of the final phase of the company's 510(k) application review. The company secured a positive resolution this summer after responding to initial FDA questions related to EvieMED's wellness features and metrics and remains optimistic on EvieMED's potential for 510(k) clearance. The EvieMED Ring is a wearable device designed to provide medical device functionality through its pulse oximetry feature, and also offer wellness metrics related to sleep, activity and logging of mood, energy and other characteristics.

08:07 EDT NaaS expands charger connections - NaaS Technology announced that as of September 30, the company has connected approximately 1.15M chargers to its charging network, a 30% increase compared to the end of 2023, outpacing the national average growth rate of 22% within the same period.

08:04 EDT Standex raises quarterly dividend 6.7% to 32c per share - Standex International announced that its Board of Directors has declared a quarterly cash dividend of 32c per share, an approximately 6.7% year-on-year increase. The dividend is payable November 22 to shareholders of record on November 8.

08:02 EDT Walgreens Boots Alliance, Veeva announce strategic partnership - Walgreens (WBA) and Veeva Systems (VEEV) announced a long-term partnership to help life sciences companies improve patient outcomes. The partnership enriches Veeva Data Cloud products and allows Walgreens to better serve life sciences through access to Veeva Data Cloud and Veeva Clinical Platform.

07:58 EDT NextSource completes first commerical shipments of graphite concentrate - NextSource Materials completed its first commercial shipments of SuperFlake graphite concentrate from its Molo Graphite Mine in southern Madagascar. Full container loads of high-quality, coarse flake graphite concentrate were exported from the Port of Tulear, Madagascar to Germany and to the United States of America under existing offtake agreements. These initial container shipments of SuperFlake graphite are destined for key demand markets for higher value graphite products, including refractory materials and graphite foils for consumer electronics and fire-retardant applications.

07:52 EDT Union Pacific expects Q4 results to be consistent with Q3 - The company said, "Fourth quarter results expected to be consistent sequentially from third quarter while improving year-over-year versus the fourth quarter 2023."

07:47 EDT Tractor Supply to acquire Allivet, terms undisclosed - Tractor Supply announced it has signed a definitive agreement to acquire Allivet, a privately held online pet pharmacy. This acquisition will also allow the company to introduce a pet and animal pharmacy solution for its 37M Neighbor's Club members. The company anticipates leveraging its store footprint and digital offerings to expand Allivet's reach and sales opportunity. For the last several years, Allivet's PetRx platform has been a partner with Tractor Supply to offer digital pet pharmacy service under the Tractor Supply brand. The transaction is subject to customary closing conditions, including receipt of applicable regulatory approvals. The transaction is expected to close in Tractor Supply's fiscal first quarter of 2025. The deal is an all-cash transaction that Tractor Supply anticipates financing through its balance sheet.

07:45 EDT Prelude Therapeutics presents new data from Phase 1 trial of PRT3789 - Prelude Therapeutics announced the presentation of additional data from its ongoing Phase 1 open-label, dose-escalation trial of PRT3789, a first-in-class, highly selective SMARCA2 degrader designed to treat cancer patients with a SMARCA4 mutation. The data were presented at a plenary session of the 36th Annual EORTC-NCI-AACR Symposium in Barcelona, Spain. The study investigators reported, as of September 23, 2024, additional follow up data on 65 patients that were enrolled, treated, and safety evaluable. PRT3789 was generally well-tolerated through 8 dosing cohorts. The majority of adverse events reported by investigators have been mild to moderate. Overall, of the 26 advanced, heavily pre-treated NSCLC or esophageal patients with Class 1 mutations evaluable for efficacy, now with additional follow up, RECIST partial responses were confirmed in 4 patients, including 2 of 9 NSCLC patients with confirmed PRs at doses of 283 mg or higher

07:43 EDT Incannex appoints Barbato as Chief Medical Officer - Incannex Healthcare (IXHL) announced the appointment of Lou Barbato, M.D., as Chief Medical Officer, CMO, effective immediately. Dr. Barbato joins Incannex from Jazz Pharmaceuticals (JAZZ), where he served as Global Medical Lead for several clinical-stage therapeutic programs addressing neurological disorders.

07:42 EDT BridgeBio shares preliminary data from CANaspire Phase 1/2 trial of BBP-812 - BridgeBio Pharma presented positive preliminary data from eleven participants dosed in the CANaspire Phase 1/2 clinical trial of BBP-812, an investigational intravenous adeno-associated virus serotype 9 gene therapy in development for the treatment of Canavan disease. Highlights of the results presented at ESGCT 2024 include: Rapid and sustained reduction of NAA in urine and brain of participants post BBP-812 dosing; Urine NAA was reduced to levels associated with mild Canavan disease; NAA in CSF was reduced an average of 70% +/- 10% twelve months after receiving the low dose; Improved myelination on T-2-weighted magnetic resonance imaging observed in the majority of participants dosed with BBP-812; Progressive and continued post-dose improvement in gross motor function and achievement of motor milestones; In the low-dose cohort, these divergent trajectories result in statistically significant improvements in achieved motor function and milestones at 12-months after treatment with BBP-812; All participants demonstrated progress on administered developmental/motor assessments as measured by the GMFM-88, HINE-2, CDC milestones, or the Canavan Disease Rating Scale BBP-812 continues to be generally well-tolerated.

07:40 EDT Midland intersects several spodumene pegmatites during drilling at Galinee - Midland Exploration, in partnership with Rio Tinto Exploration Canada, announced preliminary results from the first drilling campaign for lithium on the Galinee project, and results from surface prospecting on Galinee, Wookie, and Shire projects. The 2024 drilling campaign's main objective was to test the 2023 Iceberg, Iceberg South and Iceberg South-West lithium showings while prospecting aimed to find new showings. This press release reports results from the first thirteen drill holes of the 2024 campaign out of a total of twenty-eight. The Galinee project is located approximately 5 kilometers east of the Adina lithium deposit held by Winsome Resources, is wholly owned by Midland, and is subject to an option agreement signed with RTEC in June 2023 and amended in April 2024. Highlights: On Galinee, best results from the first thirteen drill holes out of twenty-eight: 1.38% Li2O over 37.86 meters, including 1.88% Li2O over 21.35 meters; 1.94% Li2O over 20.97 meters, and also 2.47% Li2O over 11.52 meters; 1.49% Li2O over 26.50 meters, including 1.85% Li2O over 19.20 meters; 0.89% Li2O over 33.30 meters, including 1.87% Li2O over 16.70 meters; On Galinee, at least seven meter to decameter-scale spodumene pegmatites were intersected during the 2024 drilling campaign, which remain open and further to be tested; On Galinee, two new lithium showings were identified in 2024,White Lightning and Snow Fox, with selected grab samples up to 4.62% Li2O and 4.19% Li2O respectively; On Wookie, identification of the Grogu spodumene pegmatite showing.

07:38 EDT Shyft Group cuts FY24 CapEx view to $15M-$20M from $20M-$25M - Sees FY24 free cash flow of approximately $30M.

07:37 EDT VCI Global completes Founder Group's IPO on Nasdaq - VCI Global (VCIG) announce the IPO of its client, Founder Group Limited's (FGL) on Nasdaq on October 23, 2024. FGL is a leading Malaysian solar engineering, procurement, construction and commissioning company that was spun off from Reservoir Link Energy Berhad, a Bursa Malaysia-listed company. With expertise in capital market consultancy, VCI Global facilitated FGL's entire IPO journey, culminating in its trading debut on Wednesday, which resulted in a market capitalization exceeding $65 million and raised $4.875 million. FGL is recognized as the market leader in Malaysia's solar EPCC sector, providing end-to-end EPCC solutions for solar photovoltaic facilities. As the IPO consultant for FGL, VCI Global played a crucial role in providing essential guidance and working closely with various professionals throughout the listing process, generating approximately $5.2 million in revenue for VCI Global.

07:36 EDT ZenaTech's ZenaDrone acquires drone design patent - ZenaTech announces that its subsidiary, ZenaDrone, is acquiring a United States Design Patent for a drone design pertaining to the second-generation drone design used in its ZenaDrone 1000 product. This patent includes changes to the first-generation design to improve flight times and increase the payload capacity. The patent was granted by the US Patent and Trademark Office in November 2023 by ZenaTech's former parent company. The patent acquisition is subject to shareholder and regulatory approvals that may be required.

07:30 EDT Modine Manufacturing opens 14.6 acre Bradford, UK site - Modine announced the official opening of its 14.6 acre Bradford, UK, site acquired earlier this year. This site will be dedicated to meeting demand for Airedale by Modine precision cooling products for data centers, with production launching two months ahead of schedule. As part of its global expansion strategy, Modine is able to supply global customers with precision Airedale by Modine cooling equipment, systems, and technologies from facilities across Canada, Spain, the UK, and the U.S. The Bradford site manufactures and tests computer room air handlers and fan walls; expansion plans for the site include the construction of a state-of-the-art fan wall test center for R&D activities and factory acceptance tests.

07:29 EDT NFI Group subsidiary receives new firm order from RTS - NFI Group subsidiary New Flyer of America announced a new firm order from Regional Transit Service, RTS, for 44 Xcelsior clean-diesel heavy-duty transit buses. The contract includes 24 Xcelsior 40-foot buses and 20 Xcelsior 60-foot buses. The contract was supported by a combination of federal, state, and local funding and was added to New Flyer's backlog in Q3 2024.

07:27 EDT BranchOut Food provides shareholder update - BranchOut Food unveiled transformative developments that position the company for a banner year of growth and profitability. The nation's largest warehouse club has expanded its relationship with BranchOut; BranchOut successfully launched three new private-label products at the nation's largest retailer; BranchOut has signed an initial $175k order with the nation's top salad kit producer; BranchOut has been finalizing its sales strategy for the ingredient market. "Bringing our Peru facility online marks a pivotal moment for BranchOut," said Eric Healy, CEO of BranchOut Food. "We are well-positioned to scale operations efficiently while driving profitability. As we look ahead to 2025 and beyond, we see tremendous growth opportunities fueled by increasing demand from major retailers, ingredient customers and large CPG brands. Given the rapid growth, we are exploring the acquisition of a fourth large scale machine in 2025, which would increase our production capacity from $40M to approximately $50M and support our current and future sales goals for the next two years."

07:27 EDT Surge Copper announces assay results from drill holes at Berg Project - Surge Copper announced assay results from drill holes BRG24-253 and 254, two of the ten holes completed during the 2024 field program at its 100%-owned Berg project located in central British Columbia. Both holes were collared from the same location and were targeted to infill the western portion of the deposit to support resource definition. Highlights: Hole BRG24-254 intersected 412 metres grading 0.40% CuEq2 from 36 metres depth including an interval within the supergene sulfide zone of 54 metres grading 0.53% CuEq and an interval within the hypogene system grading 0.68% CuEq over 18 metres; Hole BRG24-253 intersected 288 metres grading 0.30% CuEq from 12 metres depth to the end of the hole including an interval within the supergene sulfide zone of 56 metres grading 0.52% CuEq; Both holes are expected to upgrade sizable zones of Inferred resources on the outer and inner margins of the mineralized zone. Leif Nilsson, CEO, commented: "We are very pleased with this initial batch of results from the 2024 drill program at Berg. Holes 253 and 254 were from a series of holes that were designed to infill regions of the deposit containing predominantly Inferred resources, in hopes of both upgrading the resource estimation category and increasing the estimated grade. Both holes will help achieve these objectives, and both holes demonstrate the consistency and continuity of mineralization across large volumes at the Berg deposit."

07:25 EDT TKO Group approves capital return program, acquires sports assets from Endeavor Group - TKO Group (TKO) has authorized a share repurchase program of up to $2.0B of its Class A common stock and the initiation of a quarterly cash dividend program pursuant to which holders of TKO's Class A common stock will receive their pro rata share of $75.0M in quarterly distributions to be made by TKO Operating Company. Also today, TKO has reached a definitive agreement with Endeavor Group (EDR) to acquire Professional Bull Riders, On Location, and IMG in an all-equity transaction valued at $3.25B. PBR is a bull riding league organizing more than 200 annual live events, welcoming approximately 1.25 million fans, and reaching more than 285 million households in more than 65 territories. PBR CEO and Commissioner Sean Gleason will continue to lead the organization. On Location is a leading provider of premium experiences for fans attending more than 1,200 sporting events. On Location president Paul Caine will continue to lead the organization. IMG is one of the world's largest global distributors and producers of sports content, packages and sells media rights and brand partnerships. The acquisition of IMG does not include businesses associated with the IMG brand in licensing, models, and tennis representation, nor IMG's full events portfolio. Adam Kelly will lead IMG as president. Endeavor will receive approximately 26.14 million common units of TKO Operating Company and will subscribe for an equal number of shares of TKO's Class B common stock, with Endeavor expected to own approximately 59% of TKO alongside the other existing TKO shareholders, who will own the remaining 41% upon completion of the transaction. The transaction is expected to close in the first half of 2025.

07:24 EDT Rivian, Patagonia partner with Sol Systems for renewable energy - Rivian, Patagonia and Sol Systems have joined forces to advance renewable energy in North Carolina through a Renewable Energy Certificate and Community Impact Agreement. This partnership is centered around the 50 MWac Lick Creek Solar project in Stokes County, NC, which will supply clean energy and contribute to a more sustainable future. The project is not only a step towards reducing carbon emissions but also a demonstration of how businesses can use renewable energy procurement to create positive social and environmental impacts. The Lick Creek Solar project benefits the local community today through its infrastructure investment in clean electricity, and this procurement initiative is designed to create an additional layer of community impact. Through their collaboration, Rivian, Patagonia, and Sol Systems are committed to creating meaningful benefits for local youth. This effort follows The Nature Conservancy and Rivian's co-developed holistic "Power with Purpose" approach to renewable energy, which emphasizes both environmental and societal gains.

07:23 EDT Passage Bio delivered preclinical, interim data at ESGCT - Passage Bio announced the company delivered preclinical and interim clinical data as part of an oral presentation at the European Society of Gene & Cell Therapy, ESGCT, 31st Annual Congress being held October 22-25, 2024, in Rome, Italy. Title: "Non-clinical and early clinical development of PBFT02, an AAV gene therapy for frontotemporal dementia with GRN mutations." Data Summary: Capsid comparison study in non-human primates showed the AAV1 vector achieved superior human PGRN levels in the CSF as compared to AAV5 and AAVhu6 following intra-cisterna magna administration; Dose escalation study in Grn knockout mice showed PBFT02 improved lysosomal histopathology and reduced neuroinflammation throughout the brain following intra-CSF delivery; NHP biodistribution study showed ICM administration of PBFT02 achieved high levels of gene distribution throughout the nervous system; PBFT02 was well tolerated in NHPs, and ICM administration resulted in dose-dependent PGRN elevations in NHP CSF; Interim safety and biomarker data from the upliFT-D clinical study demonstrated that Dose 1 of PBFT02 was generally well-tolerated after ICM administration and led to consistent, durable increases in levels of CSF progranulin in all treated Cohort 1 patients

07:21 EDT Psyence recruits Empax Center as second trial site for Phase IIb trial - Psyence Biomedical announced the recruitment of Perth, Australia-based Empax Center as the second trial site for Psyence's Biomed ongoing Phase IIb clinical trial of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care. Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustment Disorder topline data in the second half of 2025

07:19 EDT Verrica to preset results on VP-315 at Fall Clinical Dermatology Conference - Verrica Pharmaceuticals announced the acceptance of two abstracts that will be presented as posters at the Fall Clinical Dermatology Conference, which is being held from October 24-27, 2024, in Las Vegas, Nevada. The posters will feature clinical data from Part 2 of the Company's Phase 2 study of the Company's novel oncolytic peptide, VP-315, for the treatment of basal cell carcinoma. The presentations are titled "Results of a Phase 2 Multicenter Study Evaluating the Safety and Tolerability of VP-315, an Investigational therapy for Basal Cell Carcinoma" and "Results of a Phase 2 Multicenter Study to Evaluate the Efficacy of VP-315, an Investigational therapy for Basal Cell Carcinoma". The posters will include safety and histologic clearance data from 82 patients with up to 2 target BCC tumors in Part 2 of the Phase 2 study evaluating VP-315 for the treatment of BCC, including patients with tumors on the head and neck. Part 2 of the Phase 2 trial was designed to further explore dosing regimens to help identify the recommended regimen for a Phase 3 study program. Approximately 51% of tumors treated in Part 2 achieved complete histological clearance and patients with residual tumor on average achieved approximately 71% reduction in tumor size. There were no Treatment Related Serious Adverse Events, and most Treatment Related Adverse Events were mild to moderate. The Company expects genomic and T-cell data in the first quarter of 2025 and plans to request an End-of-Phase 2 meeting with the FDA to determine the next steps for the development of VP-315 for the treatment of BCC in the first half of 2025.

07:18 EDT National Fuel COO Ronald Kraemer to retire, effective Feb. 1, 2025 - National Fuel Gas Company announced that Ronald Kraemer, COO of National Fuel Gas Company and President of National Fuel's pipeline and storage subsidiaries, has indicated his intention to retire effective Feb. 1, 2025, after more than 46 years with the company. Joseph Del Vecchio, Executive Vice President of National Fuel Gas Supply Corporation, will succeed him in the role of President of National Fuel Gas Supply Corporation and Empire Pipeline.

07:15 EDT EyePoint announces first patient dosed in global Phase 3 LUGANO trial - EyePoint Pharmaceuticals announced that the first patient has been dosed in the Phase 3 LUGANO clinical trial of DURAVYU, formerly EYP-1901, for the treatment of wet age-related macular degeneration. DURAVYU is an investigational sustained delivery therapy delivering patent-protected vorolanib, a selective tyrosine kinase inhibitor formulated in proprietary bioerodible Durasert E.

07:13 EDT American Airlines says 'on track' to reduce total debt from peak levels - On track to reduce total debt from peak levels by $15 billion by year-end 2025.

07:10 EDT Alkermes backs FY24 financial expectations - Alkermes reiterates its financial expectations for 2024, as set forth in its press release dated Feb. 15, 2024.

07:04 EDT Nasdaq says 'continues progress' on 2024 strategic priorities - The company said, "Nasdaq continued its progress on its 2024 strategic priorities - Integrate, Innovate, Accelerate - positioning the company to capitalize on opportunities for sustainable, scalable, and resilient growth. Integrate - Since the acquisition of Adenza nearly a year-ago, Nasdaq has actioned more than 80% of its net expense synergy target and continues to delever ahead of plan. Innovate - Nasdaq reached new milestones in deploying AI tools and products including the launch of an internal Generative AI platform with custom-built efficiency tools and completed the rollout of AI copilot tools to all of its developers. Calypso also announced an AI-based solution for X-Value Adjustments with up to 100 times faster processing speeds that improves the efficiency of risk calculations for banks, insurers, and other financial institutions. Beyond Nasdaq's AI innovations, Market Services migrated Nasdaq International Securities Exchange to its next-generation derivatives platform, Fusion. Four of Nasdaq's U.S. markets and one European equity derivatives market are operating on this platform which provides enhanced performance, including lower latency, higher throughput, and increased productivity. Accelerate - We continue to make progress on our One Nasdaq strategy driving two cross-sells across the Financial Technology division in the quarter. The percentage of cross-sell opportunities in the division's pipeline is over 10% and Nasdaq remains on track to exceed $100 million in cross-sells by the end of 2027."

07:04 EDT Southwest reaches pact with Elliott, appoints six new independent directors - Southwest Airlines announced the appointments of David Cush, Sarah Feinberg, Dave Grissen, Gregg Saretsky and Patricia Watson as independent directors of the Board in connection with Cooperation and Information Sharing Agreements reached with Elliott Investment Management L.P. In addition, Pierre Breber, former CFO of Chevron, has also been appointed to the Board of Directors. These appointments are effective as of November 1, 2024. Executive Chairman Gary Kelly will accelerate his retirement, which - along with the previously announced retirements of six other Southwest Directors - will go into effect on November 1, 2024. Following his departure from the Board and related responsibilities, Kelly will assume the title of Chairman Emeritus. The newly reconstituted Board will appoint a new independent Chairman. The Board will be reduced to 13 members as of Southwest's 2025 Annual Shareholder Meeting. As previously announced, the Board has refreshed its Finance Committee, which is responsible for assisting in the Board's oversight of the Company's operational and strategic plans. Saretsky, Cush and three additional Directors to be appointed by the reconstituted Board will serve on the Finance Committee, with Saretsky serving as Chair. Kelly said, "We are pleased to have reached a collaborative resolution with Elliott, continuing our Board refreshment with the addition of new directors who bring complementary skills and experience. I am confident this Board will continue to hold the leadership team accountable for executing its transformational plan and delivering financial performance. It has been the honor of my lifetime to work with our People and serve our Customers in making Southwest the leader it is today. I believe Southwest's best days lie ahead under the vision and leadership of Bob Jordan and the oversight of this reconstituted Board." As part of this process and to facilitate collaboration, Southwest has entered into a Cooperation Agreement under which Elliott has agreed to standstill, voting, confidentiality, and other provisions, and an Information Sharing Agreement to enable Southwest to share confidential information regarding upcoming Company announcements and other matters. Elliott has informed the Company that it withdrew its request to call a Special Meeting of Shareholders and no longer intends to nominate candidates to stand for election to the Southwest Airlines Board. The Cooperation Agreement will be filed on a Form 8-K with the U.S. Securities and Exchange Commission.

06:48 EDT Sonic Automotive raises quarterly dividend 17% to 35c per share - Payable on January 15, 2025 to all stockholders of record on December 13, 2024.

06:45 EDT TechnipFMC share repurchase authorization increased by $1B

06:26 EDT Parsons awarded $27M task order - Parsons announced that the company was awarded a Defense Threat Reduction Agency Proliferation Prevention Program task order to reduce the threat of weapons of mass destruction proliferation in Eastern Europe. The $27M ceiling-value task order under the DTRA Cooperative Threat Reduction Integrating Contract III is new work for the company and consists of a two-year period of performance and three one-year option periods. Under this task order, Parsons will provide expertise, training, and resources to allow partner nations in Eastern Europe to address existing and emerging security risks. The company will provide DTRA with program management, equipment procurement and delivery, training, sustainment, and design and construction management capabilities.

06:15 EDT Dorian LPG increases board from seven to eight directors - Dorian LPG, on the recommendation of its nominating and corporate governance committee, unanimously authorized the increase in the size of the board from seven to eight directors, and, to fill the resulting vacancy, appointed Mark Ross to serve as a Class III director effective immediately. Ross had a 34-year career at Chevron, most recently serving as the president of Chevron Shipping Company.

06:12 EDT Barclays targeting RoTE of greater than 12% in 2026 - Returns: targeting a greater than 12% RoTE; Capital returns: plan to return at least GBP 10B of capital to shareholders between 2024 and 2026, through dividends and share buybacks, with a continued preference for buybacks: Plan to keep total dividend stable at 2023 level in absolute terms, with progressive dividend per share growth driven through share count reduction as a result of increased share buybacks; Dividends will continue to be paid semi-annually. This multi-year plan is subject to supervisory and Board approval, anticipated financial performance and our published CET1 ratio target range of 13-14%; Income: targeting Group total income of c.GBP 30B; Costs: targeting total Group operating expenses of c.GBP 17B and a Group cost: income ratio of high 50s in percentage terms. This includes total gross efficiency savings of c.GBP 2B by 2026; Impairment: expect an LLR of 50-60bps through the cycle; Capital: expect to operate within the CET1 ratio target range of 13-14%: Targeting IB RWAs of c.50% of Group RWAs in 2026; Impact of regulatory change on RWAs in line with our prior guidance expected to be at lower end of 5-10% of Group RWAs; The previously estimated c.GBP 16bn RWAs impact from USCB moving to an Internal Ratings Based model remains in line with prior guidance, with a change to timing and subject to model build and portfolio changes. c.GBP 5bn of this to be reflected when Basel 3.1 is implemented in 2026 and the remainder to follow thereafter; A modest increase in Pillar 2A is likely, applicable at some point in 2025 until model implementation

06:09 EDT Barclays targeting RoTE of greater than 10% in 2024 - Returns: targeting RoTE of greater than 10% and c.10.5% excluding inorganic activity: The cumulative impact of all inorganic activity on FY24 Group RoTE is currently expected to be broadly neutral, as an estimated net gain upon the completion of the Tesco Bank acquisition in Q424 should broadly offset the losses on disposals from our Italian retail mortgage portfolios as well as from the disposal of the German consumer finance business. Income: targeting Barclays Group NII excluding IB and Head Office of greater than GBP 11B, of which Barclays UK NII is now c.GBP 6.5B; Costs: targeting Group cost: income ratio of c.63%, which includes c.GBP 1bn of gross efficiency savings in 2024; Impairment: expect an LLR of 50-60bps through the cycle; Capital: expect to operate within the CET1 ratio target range of 13-14%.

06:09 EDT Rhythm Pharmaceuticals and Axovia Therapeutics sign BBS research collaboration - Rhythm Pharmaceuticals and Axovia Therapeutics announced a joint research collaboration designed to advance the understanding of Bardet-Biedl syndrome, or BBS. BBS is a rare autosomal recessive ciliopathy that presents with a variety of signs and symptoms that evolve over time including visual impairment, renal disease, polydactyly, genital abnormalities, cognitive impairment, hyperphagia and early-onset, severe obesity arising from impairment of the hypothalamic MC4R pathway. In the United States, BBS affects approximately 4,000 to 5,000 individuals with similar prevalence in Europe.

06:05 EDT TRI Pointe sees Q4 home deliveries 1,600-1,800 - For the fourth quarter, the Company anticipates delivering between 1,600 and 1,800 homes at an average sales price between $700,000 and $710,000. The Company expects homebuilding gross margin percentage to be in the range of 23.0% to 23.5% for the fourth quarter and anticipates its SG&A expense as a percentage of home sales revenue will be in the range of 10.5% to 10.9%. Finally, the Company expects its effective tax rate for the fourth quarter to be approximately 26.0%.

06:02 EDT UPS sees FY24 adjusted operating margin ~9.6% - Sees FY24: Lifts consolidated non-GAAP adjusted operating margin expectation to approximately 9.6%; Capital expenditures of approximately $4.0B; Dividend payments expected to be around $5.4B, subject to Board approval.

05:55 EDT Wheaton Precious Metals acquires gold stream from Montage Gold for $625M - Wheaton Precious Metals (WPM) announced that its wholly-owned subsidiary, Wheaton Precious Metals International, or WPMI, has entered into a definitive Precious Metals purchase agreement with Montage Gold (MAUTF) in respect to its Kone Gold Project located in Cote d'Ivoire. WPMI will pay Montage total upfront cash consideration of $625M in four equal installment payments during construction, subject to certain customary conditions. WPMI will purchase 19.5% of the payable gold until a total of 400,000 ounces of gold has been delivered, subject to adjustment if there are delays in deliveries relative to an agreed schedule, at which point WPMI will purchase 10.8% of the payable gold until an additional 130 Koz of gold has been delivered, at which point WPMI will purchase 5.4% of payable gold for the life of the mine. Payable gold is calculated using a fixed payable factor of 99.9%. Attributable gold stream production is forecast to average over 60 Koz of gold per year for the first five years of production, over 47 Koz of gold per year for the first 10 years of production, and over 34 Koz for the life of mine. The project is forecast to have a 16-year mine life based on reserves, with first production anticipated in early 2027. WPMI will make ongoing payments for the gold ounces delivered equal to 20% of the spot price of gold. For the first five years after the Precious Metals Purchase Agreement ("PMPA") is signed, there will be a price adjustment mechanism in place if the spot price of gold is less than $2,100/oz or greater than $2,700/oz. For example, if spot gold is $3,200 per ounce, Wheaton's production payment would be $675 per ounce, equating to 21% of the spot price. This price adjustment mechanism expires on the fifth anniversary of the PMPA, after which the production payment will be equal to 20% of the spot price going forward. WPMI has also provided Montage with a secured debt facility of up to $75 million to be allocated to project costs, including cost overruns. The addition of the Kone Project will increase Wheaton's total estimated Proven and Probable Mineral gold reserves by 0.62M ounces, Measured and Indicated Mineral gold resources by 0.05 Moz and Inferred gold resources by 0.02 Moz. The Gold Stream will include a customary completion test based on expected gold production and expected mining rates. WPMI has also obtained a right of first refusal on any future precious metal streams, royalties, prepays or similar transactions. The Gold Stream will apply to a Core Area of Interest inclusive of the Kone and Gbongogo deposits, with exploration upside beyond the currently defined deposits. Ore from within a 100km Expanded Area of Interest will be subject to the stream if that ore is processed at the Kone mineral processing facility, until such time following the Second Dropdown Threshold that ounces received under the stream from the Expanded Area of Interest is equal to the remaining ounces from the Core Area of Interest, at which point the stream percentage will be reduced to nil. If at any point after that the remaining ounces from the Core Area of Interest exceed the ounces received from the Expanded Area of Interest, the company will continue receiving 5.4% of payable gold from the Core Area of Interest, for the remaining life of mine. In the event of a change of control prior to the earlier of completion and December 31, 2026, Montage will have an option to buyback one third of the stream. Montage will provide WPMI with corporate guarantees and certain other security over their assets. Montage is expected to comply in all material respects with the International Finance Corporation's Performance Standards on Environmental and Social Sustainability, the Global Industry Standard on Tailings Management, and WPMI's Partner/Supplier Code of Conduct, which outlines Wheaton's expectations in regard to environmental, social and governance matters. As at June 30, the company had approximately $540M of cash on hand and believes that when combined with the liquidity provided by the available credit under the $2B revolving term loan and ongoing operating cash flows, WPMI is well positioned to fund the acquisition of the Gold Stream as well as all outstanding commitments and known contingencies and provides flexibility to acquire additional accretive mineral stream interests.

05:33 EDT Indivior, Humana and Centene report expected settlement of antitrust litigation - The company said, "Indivior (INDV) continues to address legacy litigation to create greater certainty for all stakeholders. Today, the Group announces an expected settlement of the last remaining antitrust litigation with (i) Humana, Inc. (HUM) and certain of its affiliates (collectively, "Humana") and (ii) with Centene Corporation (CNC), Wellcare Healthcare Plans, Inc., New York Quality Healthcare Corp. (d/b/a Fidelis Care), and Health Net, LLC (collectively, "Centene"). The Group has recorded a provision of $39m reflecting the net present value (NPV) at the risk-free rate of the agreed amounts to be paid in 2024 and 2025. The parties to the settlement still must negotiate material terms and conditions of the final settlement agreement, which Indivior expects to resolve shortly. Final settlement, if reached, would resolve all of the Group's remaining legacy antitrust litigation, including all claims in the Kentucky and Pennsylvania state court actions filed by Humana, and all claims in the Virginia state court action filed by Centene."

05:16 EDT Kennedy Wilson partners with CPP Investments to launch rental housing JV - Canada Pension Plan Investment Board, or CPP Investments, has partnered with global real estate investment company Kennedy Wilson to launch a new single-family rental housing joint venture, or JV, in the United Kingdom. CPP Investments will initially commit GBP 500M, with Kennedy Wilson committing GBP 56M. The JV will have an initial target of approximately GBP 1B of asset value, including leverage, with the potential to commit further capital depending on market opportunities. CPP Investments will hold 90% of the venture and Kennedy Wilson will hold a 10% ownership interest moving forward. The investment program is seeded with properties from two developments sourced by Kennedy Wilson, including units under construction by Barratt Redrow in Norwich, where Kennedy Wilson is now leasing up the first phase of completed homes, and units by Miller Homes in Stevenage, which will deliver completed houses from Q2. Kennedy Wilson has an active pipeline of opportunities totaling over GBP 360M and 1,100 units, with the capacity to reach 4,000 units at full capital deployment.

04:28 EDT Boeing shares fall 3% to $152.62 after union rejects contract offer